Strategy Of A Corporate Split: An Interview With Mallinckrodt’s Mark Trudeau and Matt Harbaugh

CEO-designate and CFO for the Mallinckrodt specialty pharma spin-out from Covidien discuss the strategy for differentiating its products in a competitive analgesic space. Despite a goal of becoming a leading specialty pharma, the new company does not plan to divest its imaging or active pharmaceutical ingredient businesses.

Since December 2011, Dublin-based Medtronic Minimally Invasive Therapies has been planning a business split, separating its medical device-focused Covidien Ltd. from its pharmaceutical and imaging-based Mallinckrodt PLC. The Irish firm’s fiscal year ends on Sept. 27, 2013, while the split into two separate, publicly traded companies is slated to occur on June 28.

The new Mallinckrodt will retain a focus on neurology drugs, mainly in the areas of pain therapy and attention deficit/hyperactivity...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

More from Geography